Compare ALG & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALG | TERN |
|---|---|---|
| Founded | 1955 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | 1993 | 2021 |
| Metric | ALG | TERN |
|---|---|---|
| Price | $164.74 | $29.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $225.00 | $25.59 |
| AVG Volume (30 Days) | 139.5K | ★ 3.6M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | ★ 0.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 9.64 | N/A |
| Revenue | ★ $1,615,388,000.00 | N/A |
| Revenue This Year | $1.26 | N/A |
| Revenue Next Year | $5.09 | N/A |
| P/E Ratio | $17.11 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $156.30 | $1.87 |
| 52 Week High | $233.29 | $30.24 |
| Indicator | ALG | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 43.80 | 72.14 |
| Support Level | $158.61 | $25.67 |
| Resistance Level | $167.88 | $29.51 |
| Average True Range (ATR) | 4.66 | 1.98 |
| MACD | 1.43 | -0.36 |
| Stochastic Oscillator | 68.97 | 88.39 |
Alamo Group Inc is engaged in the design, manufacture, and servicing of high-quality vegetation management and infrastructure maintenance equipment for governmental, industrial and agricultural use. Its products include tractor-mounted and self-propelled mowers, zero-turn mowers, agricultural implements, tree and branch chippers, forestry/wood recycling equipment, street and parking lot sweepers, leaf and debris collection equipment, truck mounted highway attenuator trucks, vacuum trucks, hydro-excavation equipment, telescopic boom excavators, and snow removal equipment. The company's reportable segments are Vegetation Management and Industrial Equipment. It generates a majority of revenue from Vegetation Management. Geographically, it generates the majority of revenue from United States.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.